arrow
J

Jitendar Reddy

AstraZeneca
H指数:17
被引数:1,148

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies

布地奈德/格隆溴铵/富马酸福莫特罗的生物等效性研究:与新一代推进剂相比氢氟烷烃-134a在健康成年人中的相I、随机、双盲、单剂量、部分重复、三向交叉肺暴露和全身总暴露研究

2026-02-120
PRE
Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis
2017-02-0395
PREAI
In Silico-Based High-Throughput Screen for Discovery of Novel Combinations for Tuberculosis Treatment
2015-09-019
OAAI
Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate
2015-03-3161
OAAI
Optimization of Pyrrolamides as Mycobacterial GyrB ATPase Inhibitors: Structure-Activity Relationship and In Vivo Efficacy in a Mouse Model of Tuberculosis (vol 58, pg 61, 2014)
2014-08-013
OAAI
N-Aryl-2-aminobenzimidazoles: Novel, Efficacious, Antimalarial Lead Compounds
2014-07-2138
PREAI
Lead Optimization of 1,4-Azaindoles as Antimycobacterial Agents
2014-06-2077
PREAI
4-Aminoquinolone Piperidine Amides: Noncovalent Inhibitors of DprE1 with Long Residence Time and Potent Antimycobacterial Activity
2014-06-1186
PREAI
Novel N-Linked Aminopiperidine-Based Gyrase Inhibitors with Improved hERG and in Vivo Efficacy against Mycobacterium tuberculosis
2014-05-2349
PREAI
Optimization of Pyrrolamides as Mycobacterial GyrB ATPase Inhibitors: Structure-Activity Relationship and In Vivo Efficacy in a Mouse Model of Tuberculosis
2014-01-0140
OAAI
Azaindoles: Noncovalent DprE1 Inhibitors from Scaffold Morphing Efforts, Kill Mycobacterium tuberculosis and Are Efficacious in Vivo
2013-11-21139
PREAI
Thiazolopyridine Ureas as Novel Antitubercular Agents Acting through Inhibition of DNA Gyrase B
2013-10-1861
PREAI